This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Target cholesterol levels - secondary prevention of CHD

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The landmark trials regarding the use of statins in secondary prevention are the 4S (Scandinavian Simvastatin Survival Study), the CARE (Cholesterol And Recurrent Events) trial and the LIPID (Long-term Intervention with Pravastatin in Ischaemic Heart Disease).

  • these trials revealed that reduction of total serum cholesterol and low-density lipoprotein (LDL) cholesterol in the region of 25-35% using statin therapy led to a reduction in coronary heart disease (CHD) mortality by approximately the same degree
  • the trial evidence was that patients with unstable angina benefited to the same degree as to those post - myocardial infarction

NICE suggest (1):

  • start statin treatment in people with CVD with atorvastatin 80 mg. Use a lower dose of atorvastatin if any of the following apply:
    • potential drug interactions
    • high risk of adverse effects
    • patient preference
  • Target
    • for secondary prevention of CVD, aim for low-density lipoprotein (LDL) cholesterol levels of 2.0 mmol per litre or less, or non-HDL cholesterol levels of 2.6 mmol per litre or less

Notes:

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page